LAPTO contains lapatinib, a targeted tyrosine kinase inhibitor that blocks HER2 and EGFR receptors involved in tumor cell proliferation and survival. By inhibiting these pathways, the medication helps slow tumor progression and reduce cancer cell activity.
Lapatinib is mainly used for HER2-positive breast cancer, including advanced and metastatic disease. It is commonly prescribed in combination with capecitabine, letrozole, or other anticancer therapies.
Recommended for:
Clinical studies have demonstrated that lapatinib effectively suppresses HER2 receptor activity and improves progression-free survival. International clinical trials, including EGF100151 and TEACH studies, confirmed its efficacy in combination therapy for HER2-positive breast cancer, especially after trastuzumab treatment failure.
LAPTO is indicated for the treatment of HER2-positive breast cancer, including metastatic disease. It is used in combination with other anticancer agents to inhibit tumor growth and block HER2 and EGFR receptor signaling. The medication helps delay disease progression and reduce tumor spread.
The medication should be taken orally exactly as prescribed by an oncologist. Tablets are usually taken once daily at the same time each day with water. The drug is generally administered on an empty stomach, at least one hour before or after meals. Treatment duration and dosage regimen depend on the patient’s diagnosis, disease stage, and combination therapy plan.
Side Effects
